-
Something wrong with this record ?
Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines
BP. Rai, K. Parmar, B. Pradere, O. Capoun, V. Soukup, P. Gontero, F. Soria, A. Birtle, EM. Compérat, JL. Dominguez-Escrig, Y. Yuan, F. Liedberg, H. Mostafid, M. Rouprêt, JY. Teoh, M. Moschini, P. Mariappan, BWG. van Rhijn, SF. Shariat, E....
Language English Country Netherlands
Document type Journal Article, Systematic Review, Meta-Analysis, Review
- MeSH
- Carcinoma, Transitional Cell * pathology surgery therapy MeSH
- Combined Modality Therapy MeSH
- Humans MeSH
- Lymphatic Metastasis MeSH
- Kidney Neoplasms * pathology surgery therapy MeSH
- Ureteral Neoplasms * pathology surgery therapy MeSH
- Nephroureterectomy * methods adverse effects MeSH
- Practice Guidelines as Topic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Meta-Analysis MeSH
- Review MeSH
- Systematic Review MeSH
BACKGROUND AND OBJECTIVE: Given the uncertainty regarding the role of radical nephroureterectomy (RNU) as part of a multimodal treatment strategy for upper tract urothelial carcinoma (UTUC) patients with cN+ disease, we aimed to perform a systematic review and meta-analysis of the corresponding literature. METHODS: Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we identified 17 observational comparative and noncomparative studies, published between January 2000 and September 2024, evaluating UTUC patients with cTanyN+M0 disease (P) who received RNU as part of a multimodal treatment strategy (I), as compared with any treatment strategy if applicable (C), to assess oncological or postoperative outcomes (O). Meta-analyses were further performed, as appropriate. KEY FINDINGS AND LIMITATIONS: Overall, 15 studies evaluated the effectiveness of adding chemotherapy to RNU in the perioperative setting without specifying the exact timing of delivery (n = 1), in the induction setting (n = 14), or in the adjuvant setting (n = 5), while two studies evaluated the effectiveness of adding RNU to chemotherapy. Meta-analyses showed that the use of induction chemotherapy plus RNU versus RNU alone was associated with greater odds of pathological downstaging (risk ratio [RR] = 3.06; 95% confidence interval [CI] = [2.48-3.77]; p < 0.001; I2 = 0%; p = 0.44) and pathological complete nodal response (RR = 2.80; 95% CI = [2.03-3.86]; p < 0.001; I2 = 0%; p = 0.47) as well as prolonged overall survival (HR = 0.52; 95% CI = [0.42-0.64]; p < 0.001; I2 = 14%; p = 0.33) without any significant impact on the risk of overall (RR = 1.14; 95% CI = [0.79-1.64]; p = 0.48; I2 = 0%; p = 0.76) and major (RR = 0.48; 95% CI = [0.18-1.24]; p = 0.13; I2 = 0%; p = 0.87) postoperative complications. In addition, the use of induction chemotherapy plus RNU versus RNU plus adjuvant chemotherapy (HR = 0.58; 95% CI = [0.38-0.89]; p = 0.01) or chemotherapy alone (HR = 0.49; 95% CI = [0.32-0.76]; p = 0.001; I2 = 46%; p = 0.17) was associated with prolonged overall survival. Limitations include the observational design of all included studies. CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of RNU could provide the greatest oncological benefits without any significant harm in selected UTUC patients with fit general condition and resectable cN+ disease responding to induction chemotherapy. PATIENT SUMMARY: In this report, we looked at the outcomes of radical surgery in combination with systemic chemotherapy for upper tract urothelial carcinoma with clinical evidence of dissemination to the surrounding lymph nodes. We observed that the use of radical surgery was associated with the greatest oncological benefits without any increased risk of postoperative complications in patients with fit general condition and resectable disease responding to induction chemotherapy. We conclude that the use of induction chemotherapy plus radical surgery could be the best multimodal treatment strategy for these patients.
Department of Medicine London Health Science Centre Western University London Ontario Canada
Department of Pathology Medical University of Vienna Vienna Austria
Department of Urology APHP Saint Louis Hospital Université de Paris Paris France
Department of Urology Fundación Instituto Valenciano de Oncología Valencia Spain
Department of Urology San Raffaele Hospital and Scientific Institute Milan Italy
Department of Urology Skåne University Hospital Malmö Sweden
Department of Urology The Stokes Centre for Urology Royal Surrey Hospital Guildford UK
Department of Urology UROSUD La Croix Du Sud Hospital Quint Fonsegrives France
Edinburgh Bladder Cancer Surgery Western General Hospital The University of Edinburgh Edinburgh UK
Rosemere Cancer Centre Lancashire Teaching Hospitals NHS Foundation Trust Preston UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015574
- 003
- CZ-PrNML
- 005
- 20250731091104.0
- 007
- ta
- 008
- 250708s2025 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euo.2024.12.009 $2 doi
- 035 __
- $a (PubMed)39779382
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Rai, Bhavan Prasad $u Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 245 10
- $a Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines / $c BP. Rai, K. Parmar, B. Pradere, O. Capoun, V. Soukup, P. Gontero, F. Soria, A. Birtle, EM. Compérat, JL. Dominguez-Escrig, Y. Yuan, F. Liedberg, H. Mostafid, M. Rouprêt, JY. Teoh, M. Moschini, P. Mariappan, BWG. van Rhijn, SF. Shariat, E. Xylinas, A. Masson-Lecomte, T. Seisen
- 520 9_
- $a BACKGROUND AND OBJECTIVE: Given the uncertainty regarding the role of radical nephroureterectomy (RNU) as part of a multimodal treatment strategy for upper tract urothelial carcinoma (UTUC) patients with cN+ disease, we aimed to perform a systematic review and meta-analysis of the corresponding literature. METHODS: Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, we identified 17 observational comparative and noncomparative studies, published between January 2000 and September 2024, evaluating UTUC patients with cTanyN+M0 disease (P) who received RNU as part of a multimodal treatment strategy (I), as compared with any treatment strategy if applicable (C), to assess oncological or postoperative outcomes (O). Meta-analyses were further performed, as appropriate. KEY FINDINGS AND LIMITATIONS: Overall, 15 studies evaluated the effectiveness of adding chemotherapy to RNU in the perioperative setting without specifying the exact timing of delivery (n = 1), in the induction setting (n = 14), or in the adjuvant setting (n = 5), while two studies evaluated the effectiveness of adding RNU to chemotherapy. Meta-analyses showed that the use of induction chemotherapy plus RNU versus RNU alone was associated with greater odds of pathological downstaging (risk ratio [RR] = 3.06; 95% confidence interval [CI] = [2.48-3.77]; p < 0.001; I2 = 0%; p = 0.44) and pathological complete nodal response (RR = 2.80; 95% CI = [2.03-3.86]; p < 0.001; I2 = 0%; p = 0.47) as well as prolonged overall survival (HR = 0.52; 95% CI = [0.42-0.64]; p < 0.001; I2 = 14%; p = 0.33) without any significant impact on the risk of overall (RR = 1.14; 95% CI = [0.79-1.64]; p = 0.48; I2 = 0%; p = 0.76) and major (RR = 0.48; 95% CI = [0.18-1.24]; p = 0.13; I2 = 0%; p = 0.87) postoperative complications. In addition, the use of induction chemotherapy plus RNU versus RNU plus adjuvant chemotherapy (HR = 0.58; 95% CI = [0.38-0.89]; p = 0.01) or chemotherapy alone (HR = 0.49; 95% CI = [0.32-0.76]; p = 0.001; I2 = 46%; p = 0.17) was associated with prolonged overall survival. Limitations include the observational design of all included studies. CONCLUSIONS AND CLINICAL IMPLICATIONS: The use of RNU could provide the greatest oncological benefits without any significant harm in selected UTUC patients with fit general condition and resectable cN+ disease responding to induction chemotherapy. PATIENT SUMMARY: In this report, we looked at the outcomes of radical surgery in combination with systemic chemotherapy for upper tract urothelial carcinoma with clinical evidence of dissemination to the surrounding lymph nodes. We observed that the use of radical surgery was associated with the greatest oncological benefits without any increased risk of postoperative complications in patients with fit general condition and resectable disease responding to induction chemotherapy. We conclude that the use of induction chemotherapy plus radical surgery could be the best multimodal treatment strategy for these patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nefroureterektomie $x metody $x škodlivé účinky $7 D000074682
- 650 12
- $a karcinom z přechodných buněk $x patologie $x chirurgie $x terapie $7 D002295
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 12
- $a nádory močovodu $x patologie $x chirurgie $x terapie $7 D014516
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 12
- $a nádory ledvin $x patologie $x chirurgie $x terapie $7 D007680
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $7 D017410
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Parmar, Kalpesh $u Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a Capoun, Otakar $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Soukup, Viktor $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Gontero, Paolo $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Soria, Francesco $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Birtle, Alison $u Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
- 700 1_
- $a Compérat, Eva M $u Department of Pathology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Dominguez-Escrig, Jose-Luis $u Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
- 700 1_
- $a Yuan, Yuhong $u Department of Medicine, London Health Science Centre, Western University, London, Ontario, Canada
- 700 1_
- $a Liedberg, Fredrik $u Department of Urology, Skåne University Hospital, Malmö, Sweden
- 700 1_
- $a Mostafid, Hugh $u Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK
- 700 1_
- $a Rouprêt, Morgan $u GRC 5, Predictive Onco-Urology, Department of Urology, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France
- 700 1_
- $a Teoh, Jeremy Y $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Moschini, Marco $u Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy
- 700 1_
- $a Mariappan, Paramananthan $u Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, The University of Edinburgh, Edinburgh, UK
- 700 1_
- $a van Rhijn, Bas W G $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University Vienna, Vienna, Austria
- 700 1_
- $a Xylinas, Evanguelos $u Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, France
- 700 1_
- $a Masson-Lecomte, Alexandra $u Department of Urology, APHP, Saint Louis Hospital, Université de Paris, Paris, France
- 700 1_
- $a Seisen, Thomas $u GRC 5, Predictive Onco-Urology, Department of Urology, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France. Electronic address: thomas.seisen@aphp.fr
- 773 0_
- $w MED00205913 $t European urology oncology $x 2588-9311 $g Roč. 8, č. 3 (2025), s. 841-852
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39779382 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091059 $b ABA008
- 999 __
- $a ok $b bmc $g 2366430 $s 1252699
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 8 $c 3 $d 841-852 $e 20250107 $i 2588-9311 $m European urology oncology $n Eur Urol Oncol $x MED00205913
- LZP __
- $a Pubmed-20250708
